Urolithin A and the Immune System: A New Trial in Middle Age

Building on earlier findings that urolithin A, a compound the gut produces from pomegranate and walnut polyphenols, can trigger mitophagy (the clearing of damaged mitochondria), this trial asked whether that same mechanism might help the immune system age better. Fifty healthy adults aged 45 to 70 received either 1,000mg of urolithin A daily or placebo for four weeks. The urolithin A group showed improved immune cell composition, including more of the 'naive' T cells associated with a more youthful immune response, alongside enhanced mitochondrial function and reduced markers of immune exhaustion. As a phase 1, proof-of-concept trial, its main job was establishing whether this mechanism shows up in humans at all, which it did, rather than proving long-term clinical benefit; a four-week window is also too short to say anything about durability. Still, it is a well-designed, randomised, placebo-controlled human trial, a relatively rare thing in this space, and it adds real weight to urolithin A's evidence base.